# Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/KPTI
## Company Profile
- Ticker: KPTI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Hematology
## Stock Data
- Close: 1.91 USD
- Market cap: 209178963.89000002 USD
- Last updated: 2026-08-05
## Business Overview
### Nuclear Export Oncology Company
Karyopharm Therapeutics is a commercial-stage oncology company built around inhibition of exportin 1, a nuclear export protein involved in cancer-cell survival.
### XPOVIO Franchise
XPOVIO, or selinexor, is commercialized in hematologic malignancies and provides the commercial base for development in additional cancers.
### Selinexor Mechanism
Selinexor inhibits exportin 1 to retain tumor-suppressor proteins inside the nucleus, creating a common biological strategy across hematologic and solid tumors.
### Myelofibrosis Programs
The Phase 3 SENTRY study evaluates once-weekly selinexor with ruxolitinib in JAK inhibitor-naïve myelofibrosis. SENTRY-2 evaluates selinexor in patients previously treated with JAK inhibitors.
### Endometrial Cancer and Multiple Myeloma
Karyopharm is also studying maintenance selinexor in advanced or recurrent endometrial cancer and in the Phase 3 XPORT-MM-031 study in multiple myeloma.
## Why The Stock Is Moving

As of Aug 5, 2026, KPTI closed down 2.55% at $1.91. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline data from the Phase 3 XPORT-EC-042 endometrial cancer trial are expected in mid-2026.
- Additional topline data from the 60 mg cohort of the Phase 2 SENTRY-2 myelofibrosis trial are expected in the second half of 2026.
- Topline data from the event-driven Phase 3 XPORT-MM-031 trial are expected in the second half of 2026.

## Recent News
- 2026-08-03 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635--8e9e1f10) — Source: Karyopharm Therapeutics
- 2026-07-30 20:06 EST — [Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway](https://biopharmsignal.com/news/KPTI/karyopharm-plans-to-submit-snda-for-selinexor-plus-ruxolitinib-in-myelofibrosis--3856c192) — Source: Karyopharm Therapeutics
- 2026-07-30 20:05 EST — [Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer](https://biopharmsignal.com/news/KPTI/karyopharm-announces-topline-results-from-phase-3-xport-ec-042-trial-in-endometr-a31032de) — Source: Karyopharm Therapeutics
- 2026-07-01 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-cc27221e) — Source: Karyopharm Therapeutics
- 2026-06-03 20:15 EST — [Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026](https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-in-webcast-featuring-endometrial-cancer-key-opinion-leader-on-june-8-2026) — Source: Karyopharm Therapeutics